Iterum Therapeutics plc — Director's Dealing 2018

May 31, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Iterum Therapeutics plc (ITRM)
CIK: 0001659323
Period of Report: 2018-05-30

Reporting Person: Sofinnova Venture Partners IX, L.P. (10% Owner)
Reporting Person: POWELL MICHAEL (10% Owner)
Reporting Person: Sofinnova Management IX, L.L.C. (10% Owner)
Reporting Person: Mehra Anand (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-05-30	Ordinary Shares	C	721408	—	Acquired	721408	Direct
2018-05-30	Ordinary Shares	C	275446	—	Acquired	996854	Direct
2018-05-30	Ordinary Shares	C	229660	—	Acquired	1226514	Direct
2018-05-30	Ordinary Shares	P	500000	$13	Acquired	1726514	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-05-30	Series A Preferred Shares	$	C	721408	Disposed		Ordinary Shares (721408)	Direct
2018-05-30	Series B-1 Preferred Shares	$	C	275446	Disposed		Ordinary Shares (275446)	Direct
2018-05-30	Series B-2 Preferred Shares	$	C	229660	Disposed		Ordinary Shares (229660)	Direct

Footnotes

F1: The Series A Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer.

F2: These shares are held directly by Sofinnova Venture Partners IX, L.P. (the "Fund"). The general partner of the Fund is Sofinnova Management IX, L.L.C. (the "GP") and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Fund. Dr. James I. Healy, Michael F. Powell, Ph.D., and Dr. Anand Mehra are the managing members of the GP and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by the Fund. Each of the reporting persons disclaims beneficial ownership of such shares, except to the extent of his, her or its proportionate pecuniary interest therein, if any.

F3: The Series B-1 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer.

F4: The Series B-2 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer.

F5: Not applicable.